Prescription Medicines
Forte-V Tab.50mg
- Product Category
- Erectile dysfunction treatment
- Active Ingredients
- Sildenafil citrate
- Appearance
- Purple hexagonal film-coated tablets
01 / 02
1. Composition and Strength
1 tablet
- Active ingredient: Sildenafil citrate (USP)----70.23mg (50mg as sildenafil)
- Additives (tar color aluminum lake): Red No. 3, Red No. 40, Blue No. 2
- Other additives: Anhydrous calcium hydrogen phosphate, microcrystalline cellulose, magnesium stearate, Opadry II purple (85F600000), Opadry FX silver (62W28547), croscarmellose sodium
2. Effectiveness
Treatment of erectile dysfunction
3. Dosage and dosage
As sildenafil, the recommended dose of 25 to 50 mg is administered orally once a day about 1 hour before sexual activity, and in some cases, it can be administered 4 hours to 30 minutes before sexual activity.
The dosage may be increased or decreased depending on effectiveness and tolerability.
In the following patients, the initial dose should be adjusted to 25 mg because the plasma concentration of sildenafil may increase.
- Age 65 or older (AUC 40% increase)
- Liver failure (cirrhosis: 80%)
- Severe renal failure (creatinine clearance less than 30 mL/min: 100%)
- When used in combination with CYP3A4 inhibitors (ketoconazole, itraconazole, erythromycin (182%), etc., saquinavir (210%)), the effect and adverse reaction rate may increase as the blood concentration increases.
- For patients taking ritonavir concomitantly, the maximum single dose should not exceed 25 mg over 48 hours.
4. Precautions for use
1. Warning
1) If any type of nitrate preparation or NO donor (nitroglycerin, amine nitrite, isosorbide nitrate) is taken before, during or after treatment with this drug, the blood pressure lowering effect may be enhanced and blood pressure may fall excessively. Therefore, the doctor must sufficiently confirm that the patient has not taken nitrate preparations or NO donor before prescribing this drug, and avoid administering nitrate preparations or NO donor during and after treatment with this drug. Be careful.
2) In foreign countries, as a result of post-marketing adverse reaction monitoring, adverse reactions such as death due to cardiovascular adverse reactions have been reported, so the presence or absence of cardiovascular disorders must be sufficiently confirmed.
3) Since the possibility of cardiac risk increases when patients with cardiovascular disease engage in sexual activity, treatments for erectile dysfunction, including this drug, should not be used in patients for whom sexual activity is not recommended considering the cardiovascular condition.
4) This drug has systemic vasodilatory properties (mean maximum reduction: 8.4/5.5 mmHg), resulting in a transient decrease in supine blood pressure in healthy volunteers. This may not be important in normal patients, but before administering this drug, doctors and pharmacists should carefully consider the possibility that patients with underlying cardiovascular diseases may experience adverse reactions due to this vasodilation effect, especially when engaging in sexual activity.
5) There is no established clinical data on the effectiveness or safety of this drug for the following patients. Caution must be exercised when administering this drug.
- Patients who have had life-threatening arrhythmia within the past 6 months
- Patients with heart failure or coronary artery disease causing unstable angina
- Patients with low blood pressure (less than 90/50) or patients with high blood pressure (more than 170/100)
- Patients with retinitis pigmentosa
6) Prolonged erection for more than 4 hours and priapism (painful erection for more than 6 hours) have been rarely reported after marketing. If an erection persists for more than 4 hours, you should immediately seek medical help and diagnosis. If priapism is not treated right away, it can cause penile tissue damage and permanent loss of erectile function.
7) Patients who have left ventricular outflow obstruction (e.g. aortic stenosis and idiopathic hypertrophic subaortic stenosis) or whose ability to autoregulate blood pressure is severely impaired may be sensitive to the action of vasodilators, including PDE5 inhibitors.
8) Concomitant use of ritonavir, a protease inhibitor, increases the blood concentration of sildenafil by approximately 11 times, so caution should be exercised when administering this drug to patients taking ritonavir. There are limited data from patients exposed to high doses of sildenafil. When exposed to high concentrations of sildenafil, the frequency of visual abnormalities was higher. Decreased blood pressure, syncope, and priapism have been reported in some healthy volunteers exposed to high doses of sildenafil (200-800 mg). To reduce the possibility of adverse reactions in patients taking ritonavir, it is recommended to take a reduced dose of sildenafil.
2. Do not administer to the following patients
1) Patients with hypersensitivity to this drug or its components
2) Patients who regularly or intermittently take any type of organic nitrate preparation (nitroglycerin, isosorbide nitrate, amine nitrite, sodium nitroprusside)
: If you need to take nitrate preparations after taking this medicine, it is not known when it is safe to take them. Based on the pharmacokinetic profile of a single 100 mg oral dose administered to healthy normal volunteers, the plasma concentration of this drug at 24 hours is approximately 2 ng/mL (peak plasma concentration is approximately 440 ng/mL).
In the following patients: those aged 65 years or older, those with liver failure (e.g., cirrhosis), those with severe renal insufficiency (e.g., creatinine clearance less than 30 mL/min), and those taking a strong inhibitor of CYP3A4 (e.g., erythromycin), plasma concentrations of this drug at 24 hours after dosing have been observed to be 3-8 times higher than those observed in healthy volunteers. Although the plasma concentration of sildenafil 24 hours after administration is much lower than the peak plasma concentration, it is not known whether it is safe to use nitrate drugs together at this time.
3) Patients for whom sexual activity is not recommended, including cardiovascular disease: Patients with severe cardiovascular disease such as unstable angina or severe heart failure.
4) Patients with severe liver failure
5) Patients with hypotension (blood pressure less than 90/50 mmHg) or uncontrolled hypertension (resting systolic blood pressure exceeding 170 mmHg, resting diastolic blood pressure exceeding 100 mmHg)
6) Patients who have had a life-threatening cerebral infarction, cerebral hemorrhage, stroke, or myocardial infarction within the past 6 months
7) Patients with retinitis pigmentosa (a small number of patients with retinitis pigmentosa have a genetic disease of PDE of the retina)
8) Patients taking other erectile dysfunction drugs (the safety and effectiveness of co-administration of this drug with other erectile dysfunction drugs has not been studied)
9) Patients who have lost vision in one eye due to nonarteritic anterior ischemic optic neuropathy (NAION), regardless of previous PDE5 inhibitor use.
10) Children and women under 18 years of age
11) Patients taking amiodarone hydrochloride (oral medication)
12) Patients taking guanylate cyclase stimulants such as Riociguat (potentially may cause symptomatic hypotension such as lowering blood pressure)
3. Administer with caution to the following patients:
1) Patients with anatomical deformity of the penis (angulation, corpora cavernosa fibrous tissue hyperplasia or Peyronie's disease)
2) Patients with conditions that may predispose to priapism (sickle cell disease, multiple myelopathy, leukemia)
3) Patients with bleeding abnormalities or active peptic ulcers (It appears to enhance the platelet aggregation inhibition effect of sodium nitroprusside. Safety in patients with bleeding abnormalities or active peptic ulcers has not been established.)
4) Elderly (since it has been observed that blood concentration increases in elderly people, the initial dose should be started with a low dose (25 mg).)
5) Patients with severe renal failure (creatinine clearance rate less than 30 mL/min) (Since an increase in plasma concentration was observed, the initial dose should be started with a low dose (25 mg).)
6) Patients with liver failure (since an increase in plasma concentration was observed, the initial dose should be started with a low dose (25 mg).)
7) Patients taking CYP3A4 inhibitors (since an increase in plasma concentration was observed, the initial dose should be started with a low dose (25 mg).)
8) Patients taking carperitide
9) Patients with diabetic retinopathy (As the safety of this drug in patients with diabetic retinopathy has not been studied, it should be administered after carefully conducting a benefit-harm evaluation.)
10) For patients who require the maximum recommended dose of 100 mg, the rate of adverse reactions may increase.
11) When administering to patients with cardiovascular disease who have not had sexual intercourse for several years, or patients with a history of cerebral infarction, cerebral hemorrhage, or myocardial infarction, the presence or absence of cardiovascular disease must be sufficiently confirmed. Before starting treatment with this drug, their cardiovascular status should be carefully evaluated.
In patients with cardiovascular risk factors, sexual activity may pose a potential cardiac risk. Patients who have experienced related symptoms (e.g., angina, dizziness, nausea) when starting sexual activity should refrain from further activities and consult a doctor or pharmacist about the symptoms.
12) Patients with multiple systemic atrophy (idiopathic orthostatic hypotension (Shy-Drager syndrome, etc.)) (The vasodilator action of this drug may worsen the hypotensive condition caused by the patient's underlying disease.)
4. Adverse reactions
Adverse reactions were generally transient and mild to moderate in severity. In fixed-dose studies, the incidence of some adverse reactions increased with dose. The adverse reaction characteristics of the variable-dose study, which more closely reflected the recommended dosage, were also similar to those of the fixed-dose study.
A. 74 double-blind, placebo-controlled phase 2//3/4 clinical trials
The most commonly reported adverse reactions were headache and flushing.
Adverse reactions reported in clinical trials (74 double-blind, placebo-controlled phase 2//3/4 trials) and post-marketing surveillance are listed in descending order of severity for each organ system as shown in [Table 1] below.
[Table 1] Adverse reactions reported in clinical trials and post-marketing surveillance
(Please refer to the attached document for further details)
*Adverse reactions reported only in post-marketing surveillance
At doses above the recommended dosage range, adverse reactions appeared similar to those above, but were generally reported more frequently.
B. Clinical trials for approval of Viagra
1) In six variable-dose, placebo-controlled clinical trials, the following adverse reactions were reported when this drug was administered at the recommended dose.
[Table 2.] (Please refer to the attached document for further details)
2) Among the adverse reactions that occurred in more than 2%, those that occurred at the same rate in the placebo group were as follows: respiratory tract infection, back pain, influenza syndrome, and joint pain.
3) In a fixed dose study, indigestion (17%) and visual abnormalities (11%) occurred more frequently at a dose of 100 mg than at doses lower than that. The above adverse reactions occurred at doses higher than the recommended dose, but the frequency was higher.
4) The following adverse reactions occurred in less than 2% of patients in 6 variable-dose, controlled clinical trials, but the causal relationship with this drug is not clear. Reported adverse reactions were those possibly related to drug use, and minor adverse reactions that were not accurate enough to be considered related were excluded.
(1) Whole body: infection, facial swelling, photosensitivity reaction, shock, asthenia, pain, chills, accidental fall, abdominal pain, allergic reaction, chest pain, accidental trauma.
(2) Cardiovascular system: angina, atrioventricular block, migraine, syncope†, tachycardia†, palpitations†, hypotension†, postural hypotension, myocardial ischemia, cerebral thrombosis, cardiac arrest, heart failure, electrocardiogram abnormalities, cardiomyopathy, vasodilatation.
(3) Digestive system: Nausea†, vomiting†, glossitis, colitis, dysphagia, gastritis, gastroenteritis, esophagitis, stomatitis, dry mouth†, liver function abnormality, rectal bleeding, gingivitis.
(4) Blood and lymphatic system: anemia and leukopenia.
(5) Metabolic and nutritional systems: thirst, edema, gout, unstable diabetes, hyperglycemia, peripheral edema, hyperuricemia, hypoglycemia, hypernatremia.
(6) Skeletal muscular system: arthritis, arthrosis, muscle pain†, tendon rupture, tenosynovitis, bone pain, myasthenia gravis, synovitis.
(7) Nervous system: Ataxia, hypertonia, neuralgia, neuropathy, paresthesia, tremor, dizziness, depression, insomnia, drowsiness†, dream abnormalities, decreased reflex function, decreased perception.
(8) Respiratory system: Asthma, difficulty breathing, laryngitis, pharyngitis, sinusitis, bronchitis, increased sputum, increased cough, rhinitis†.
(9) Skin and appendages: urticaria, herpes simplex, itching, sweating, skin ulcers, contact dermatitis, exfoliative dermatitis.
(10) Special organs: sudden hearing loss or hearing loss, mydriasis, conjunctivitis, glare†, tinnitus, eye pain†, otalgia, eye hemorrhage, cataract, dry eye syndrome†.
(11) Urogenital system: cystitis, enuresis, frequent urination, breast enlargement, urinary incontinence, ejaculation disorder, genital edema and dysorgasmia, and prostate abnormalities.
† Adverse reactions listed in Table 1
In an analysis of double-blind, placebo-controlled clinical trials with more than 1,300 person-years of observation for the sildenafil group and more than 700 person-years for the placebo group, there was no difference in the incidence of myocardial infarction and mortality due to cardiovascular disease in the patient group administered sildenafil compared to the placebo group. The incidence of myocardial infarction was 1.1 per 100 person-years in both the sildenafil and placebo groups. The mortality rate from cardiovascular disease was 0.3 per 100 person-years in both groups.
5) As a result of domestic clinical trials, it has been reported that the incidence of adverse reactions such as flushing, headache, and visual abnormalities is higher than the results of foreign clinical trials.
c. Post-marketing surveillance
1) Serious cardiovascular adverse reactions such as myocardial infarction, sudden cardiac death, ventricular arrhythmia, cerebrovascular hemorrhage, transient angina attack, and hypertension have been temporarily reported after marketing in relation to the use of this drug. Most of these patients had cardiovascular risk factors, and many of these adverse reactions occurred during or immediately after sexual activity, and in some cases, it was reported that they occurred immediately after using this drug without sexual activity. In other cases, it occurred several hours to several days after using this drug or having sexual intercourse. It is not known whether these adverse reactions are directly related to this drug, related to sexual activity, related to underlying cardiovascular disease, a combination of these factors, or due to other factors.
2) Sudden hearing loss or hearing loss was rarely reported after marketing, and this appeared to have a tentative correlation with PDE5 inhibitors, including this drug. In some cases, it has been reported that disease status and other factors may be associated with hearing-related adverse reactions, but in most cases, medical follow-up information that could support this association was not confirmed. It is not known whether these adverse reactions are directly related to the administration of this drug, due to the patient's inherent hearing loss risk factors, a combination of these, or other factors.
3) Tachycardia†, hypotension†, and syncope† have been reported after marketing.
4) In rare cases, there have been reports of hypotension as an adverse reaction after co-administration of sildenafil with α-blockers.
5) Other adverse reactions reported after marketing in relation to this drug, which have a tentative causal relationship with this drug, but which were not confirmed in pre-marketing clinical trials, are as follows.
(1) Nervous system: anxiety
(2) Genitourinary system: prolonged erection†, hematuria
(3) Vascular abnormalities: nosebleed†
(4) Systemic: Hypersensitivity†
(5) Eyes: Double vision, temporary loss of vision/reduced vision, redness, eye burning, eye swelling/pressure, increase in intraocular pressure, retinal vascular disease and hemorrhage, vitreous detachment/contraction and myoretinal macular edema, non-arterial anterior ischemic optic neuropathy*
† Adverse reactions listed in Table 1
*Non-arteritic anterior ischemic optic neuropathy (NAION), which causes vision decline, including permanent vision loss, has been rarely reported in post-marketing surveillance and has been shown to be tentatively related to all PDE5 inhibitors, including this drug. Most, but not necessarily, patients had anatomical or vascular risk factors that may predispose to non-arterial anterior ischemic optic neuropathy: low cup/disc ratio, age over 50 years, diabetes, hypertension, coronary artery disease, hyperlipidemia, and smoking.
An observational study evaluating whether recent use of PDE5 inhibitor drugs was associated with the acute onset of non-arterial anterior ischemic optic neuropathy showed that the risk of non-arterial anterior ischemic optic neuropathy increased approximately two-fold within 5 times the half-life after administration of PDE5 inhibitors. According to published literature, the annual incidence of non-arterial anterior ischemic optic neuropathy is 2.5-11.8 cases per year per 100,000 men aged 50 years or older.
6) Domestic post-marketing survey results
(1) Results of a usage survey conducted on 8,751 patients with erectile dysfunction
① As a result of a post-marketing use results survey conducted on 8,751 people for re-examination in Korea, the case rate of adverse reactions regardless of causal relationship with the drug was found to be 6.62% (579 people, 701 cases/8,751 people), and among these, adverse reactions for which a causal relationship with this drug could not be ruled out were 6.21% (543/8,751 people).
Flushing was the most frequently reported event at 3.75% (328/8,751 patients), followed by headache at 1.83% (160/8,751), dyspepsia at 0.23% (20/8,751), dizziness and palpitations at 0.22% each (19/8,751 each), ocular hyperemia at 0.15% (13/8,751), and visual disturbances at 0.11% (10/8,751).
In addition, adverse reactions reported less than 0.1% are classified by organ system as follows.
- Central and peripheral nervous system: migraine, confusion
- Digestive system: diarrhea, nausea, hiccups, dry mouth, vomiting, abdominal pain, dysphagia, gastric ulcer, gastroesophageal reflux, gastrointestinal disorders, abdominal distension
- Eyes: Visual impairment, double vision, dry eyes
- Cardiovascular system: tachycardia, vasodilatation, hypotension
- Respiratory system: rhinitis, nasal congestion, difficulty breathing, upper respiratory tract infection
- Liver and biliary system: increased AST, increased ALT
- Mental nervous system: anxiety, insomnia, somnolence
- Reproductive system: priapism, genital pain
- Others: redness of lips, edema, general warmth, facial edema, chest pain, asthenia, paresthesia, fatigue, increase in non-protein content, sweating, erythema, itching, muscle pain
② Among these, new adverse reactions that did not appear in pre-marketing clinical trials and a causal relationship with the drug cannot be ruled out were reported in 3 cases of general fever, 2 cases each of hiccups and erythema, and 1 case each of redness of the lips, gastric ulcer, gastroesophageal reflux, gastrointestinal disorder, and increased non-protein content.
(2) Result of spontaneous adverse reaction reporting
① Among the adverse reactions voluntarily reported after marketing in Korea, adverse reactions that were not confirmed in pre-marketing clinical trials but were assessed as having a tentative causal relationship with this drug in existing post-marketing investigations included redness of the eyes, priapism, decreased vision, increased intraocular pressure, hematuria, retinal vascular disease and hemorrhage, anxiety, temporary loss of vision, retinal detachment, epistaxis, eye swelling, and prolonged erection.
② The following adverse reactions are added according to the analysis and evaluation of domestic adverse reaction reporting data.
- Whole body: facial flushing, infection/tuberculosis, extremity pain
- Liver and biliary system: Hepatitis/Virus
- Urogenital system: penile dysfunction, painful urination, polyuria
- Eyes: Glaucoma, galactorrhea
- Neoplasm: Gastric carcinoma
- Skin: Seborrheic
D. Clinical trials in Japan
At the time of approval, adverse reactions were observed in 40 (25.48%) of 157 subjects who took this drug (doses used in the study: 25 mg to 50 mg), and abnormalities in clinical laboratory tests were observed in 31 (19.75%).
Frequently reported adverse reactions include headache (20 people; 12.74%), flushing (16 people; 10.19%), and visual abnormalities (chromopia 1 person, photophobia 1 person, conjunctivitis 1 person: a total of 3 people 1.91%). A frequently observed abnormality in clinical laboratory tests was an increase in creatine kinase (CK), which was observed in 9 of 132 cases (6.82%) receiving sildenafil.
Patients who experience the following adverse reactions should, if necessary, reduce the drug administration dose or discontinue administration and take appropriate measures to treat the adverse reactions. (Please refer to the attached document for details.)
5. General precautions
1) Patients eligible for this drug should be limited to those who require clinical treatment based on an objective diagnosis by conducting a medical history and examination to diagnose erectile dysfunction and underlying diseases.
2) Because sexual activity carries heart risks, you should pay attention to your cardiovascular condition before starting treatment. Because this drug has a blood pressure lowering effect through vasodilation, it can enhance the blood pressure lowering effect of nitrates or NO donors.
3) Patients who have experienced a cerebral infarction, cerebral hemorrhage, or myocardial infarction within the past 6 months should not take the drug. When administering the drug to a patient with a previous history of a cerebral infarction, cerebral hemorrhage, or myocardial infarction, the presence or absence of cardiovascular disease must be sufficiently confirmed.
4) Since it has been reported in animal experiments that sildenafil shows high affinity for the melanin-rich retina, caution should be exercised, such as performing ophthalmologic examinations, during long-term administration of this drug.
5) Effects on the ability to drive and use machines: In clinical trials, some patients who took this drug, especially when administered 100 mg, reported visual abnormalities and dizziness due to administration of this drug, so caution should be taken when driving or operating machines. Before patients drive or operate machinery, they should know how they react to this medication and their doctor should advise them accordingly.
6) When this drug is administered simultaneously to patients receiving alpha-blockers, symptomatic hypotension may be induced in rare cases in some patients. Therefore, when taking more than 25 mg of this drug and an alpha-blocker together, this drug should not be administered within 4 hours after administering the alpha-blocker. To minimize the occurrence of such postural hypotension, before using this drug for the first time, it must be confirmed that the patient is hemodynamically stable on alpha-blockers, and consideration should be given to starting the initial dose at a low dose. Additionally, doctors should instruct patients on what to do if symptoms of postural hypotension appear.
7) In a drug interaction study, when amlodipine 5 mg, 10 mg and Amlodipine 100 mg were co-administered to patients with hypertension, it was observed that diastolic blood pressure and systolic blood pressure decreased by an average of 7 mmHg and 8 mmHg, respectively. Drug interactions between this drug and other antihypertensive medications have not been studied.
8) This drug had no effect on bleeding time when taken alone or with aspirin. In vitro studies using human platelets show that sildenafil enhances the anti-aggregation effect of sodium nitroprusside. The combination of this drug and heparin has an additive effect on bleeding time in anesthetized rabbits, but this interaction has not been studied in humans.
9) If sudden vision loss occurs in the patient's eyes (one or both eyes), the doctor should advise the patient to stop using PDE5 inhibitors, including this drug, and take medical attention. These symptoms may be a sign of nonarteritic anterior ischemic optic neuropathy (NAION), a condition that causes vision decline, including permanent vision loss, which has been rarely reported in post-marketing surveillance and has been shown to be tentatively related to the administration of all PDE5 inhibitors, including this drug. If sudden vision loss occurs, patients should be informed to stop taking this medicine and consult a doctor immediately.
People who have previously experienced non-arterial anterior ischemic optic neuropathy are at a higher risk of recurrence of non-arterial anterior ischemic optic neuropathy. Therefore, doctors should inform these patients of these risks and that the use of PDE5 inhibitors may affect the occurrence of adverse reactions. Caution should be exercised when using PDE5 inhibitors, including this drug, in these patients, and should be used only when the expected benefits outweigh the risks.
10) If sudden hearing loss or hearing loss (which may be accompanied by tinnitus and dizziness) occurs, the doctor should advise the patient to stop using PDE5 inhibitors, including this drug, and seek immediate medical attention.
11) This drug is not an aphrodisiac or stamina enhancer, so it cannot be used for purposes other than the treatment of erectile dysfunction patients.
12) When taken with food, the onset of effect may be delayed compared to when administered on an empty stomach.
13) Use of this medicine cannot prevent diseases transmitted through sexual intercourse.
14) No tests have been conducted on the safety and effectiveness of co-administration of this drug with other PDE5 inhibitors, pulmonary arterial hypertension (PAH) treatments containing sildenafil, or other erectile dysfunction treatments, and such co-administration is not recommended.
6. Interaction
1) Drugs that increase blood concentration of this drug
(1) In in vitro studies, the metabolism of sildenafil is mainly mediated by CYP3A4 (major pathway) and 2C9 (minor pathway). Therefore, these CYP450 inhibitors may increase blood concentrations of sildenafil.
(2) In an in vivo study, cimetidine (800 mg), a non-specific CYP450 inhibitor, increased the plasma concentration of sildenafil by 56% when co-administered with this drug (50 mg) to healthy volunteers.
(3) Administration of a single 100 mg dose of this medicine during steady-state treatment with the moderate CYP3A4 inhibitor erythromycin (500 mg twice daily for 5 days) increased systemic exposure to sildenafil (AUC) by 182%. In a study in healthy male volunteers, coadministration of a single 100 mg dose with the HIV protease inhibitor saquinavir, a CYP3A4 inhibitor, at steady state (1,200 mg three times daily) increased sildenafil Cmax and AUC by 140% and 210%, respectively. More potent CYP3A4 inhibitors, such as ketoconazole and itraconazole, may have a greater effect.
(4) Patient population data from clinical studies showed a decrease in sildenafil clearance when coadministered with CYP3A4 inhibitors such as ketoconazole, erythromycin, or cimetidine.
(5) Systemic exposure to sildenafil increases when administered concurrently with CYP3A4 inhibitors, so the dose of this drug may need to be reduced depending on tolerability.
(6) Ritonavir, an HIV protease inhibitor, is a very strong CYP450 inhibitor. In a study on healthy male volunteers, when administered in steady state (500 mg, twice daily) with this drug (100 mg, single dose), the Cmax and AUC of sildenafil increased by 300% (4-fold) and 1000% (11-fold), respectively. Compared to the plasma concentration of about 5 ng/mL when sildenafil was administered alone, the plasma concentration was maintained at about 200 ng/mL even after 24 hours. This is consistent with the fact that ritonavir has pronounced effects on a wide range of CYP450 substrates.
(7) Although the interaction between other protease inhibitors and this drug has not been studied, it is expected that the blood concentration of sildenafil will increase when administered together.
(8) When the recommended dose of sildenafil was administered to patients taking a strong CYP3A4 inhibitor, the maximum free plasma concentration of sildenafil did not exceed 200 nM in any patient and was always well tolerated.
(9) In a study in healthy male volunteers, when the endothelin antagonist bosentan (CYP3A4 [moderate], CYP2C9 inducer and possibly CYP2C19 inducer) was coadministered at steady state (125 mg twice daily) with steady-state sildenafil (80 mg three times daily), the AUC and Cmax of sildenafil were 62.6%, respectively. and decreased by 55.4%. Sildenafil increased the AUC and Cmax of bosentan by 49.8% and 42%, respectively.
(10) When coadministered with a strong CYP3A4 inducer such as rifampin, a significant decrease in sildenafil plasma concentration is expected.
(11) Single administration of antacids (magnesium hydroxide/aluminum hydroxide) did not affect the bioavailability of this drug.
(12) As a result of population pharmacodynamic data analysis, CYP2C9 inhibitors such as tolbutamide and warfarin, SSRI agents (selective serotonin reuptake inhibitors), CYP2D6 inhibitors such as tricyclic antidepressants, thiazides and diuretics of this class, ACE inhibitors, and calcium channel blockers had no effect on the pharmacokinetics of sildenafil. The AUC of the active metabolite, N-desmethyl sildenafil, was increased by 62% by loop diuretics and potassium-sparing diuretics and by 102% by non-specific beta blockers. This effect on metabolites does not appear to be of clinical significance.
(13) In healthy male volunteers, there is no evidence that azithromycin (500 mg per day for 3 days) affects the AUC, Cmax, Tmax, elimination rate constant, and half-life of sildenafil or its major circulating metabolites.
(14) There is no information on the interaction between sildenafil and cyclosporine.
2) The effect of this drug on other drugs
(1) In in vitro studies, sildenafil is a mild inhibitor of CYP-450 isoforms 1A2, 2C9, 2C19, 2D6, 2E1, and 3A4 (IC50: > 150 μM). Considering that the peak plasma concentration of sildenafil after administration of the recommended dose is approximately 1 μM, this drug is unlikely to change the clearance of this isoenzyme substrate.
(2) In an in vivo study, when 100 mg of this drug was administered in combination with 5 mg and 10 mg of amlodipine to patients with hypertension, supine blood pressure decreased by an average of 8 mmHg and 7 mmHg in systolic and diastolic periods, respectively.
(3) There is no information on the interaction of this drug with non-specific PDE inhibitors such as theophylline or dipyridamole.
(4) In in vivo studies, there were no significant drug interactions with tolbutamide (250 mg) or warfarin (40 mg), which are metabolized by CYP2C9.
(5) This drug (50 mg) did not increase the delay in bleeding time caused by aspirin (150 mg).
(6) Sildenafil slightly reduces diastolic blood pressure in the supine and reclined positions (3.5 and 6.1 mmHg, respectively) in healthy subjects with a blood alcohol level of 80 mg/dL.
(7) Sildenafil (100 mg) did not affect the steady-state pharmacokinetics of the HIV protease inhibitors saquinavir and ritonavir, which are substrates for CYP3A4, in a study on healthy male volunteers.
(8) Sildenafil increased the AUC and Cmax of bosentan (125 mg, twice daily) by 49.8% and 42% in steady state (80 mg administered three times a day) (see 1) Drugs that increase blood concentration of this drug).
3) When the alpha-blocker doxazosin (4 mg and 8 mg) and sildenafil (25 mg, 50 mg, or 100 mg) were administered simultaneously to patients with benign prostatic hyperplasia receiving doxazosin, blood pressure in the lying position decreased by an average of 7/7 mmHg, 9/5 mmHg, and 8/4 mmHg, respectively, and blood pressure in the standing position decreased by an average of 6/6, respectively. A further decrease of mmHg, 11/4 mmHg, and 4/5 mmHg was observed. When sildenafil in doses higher than 25 mg were simultaneously administered to patients receiving doxazosin, patients who experienced symptomatic postural hypotension, including drowsiness and dizziness, were rarely reported within 1 to 4 hours after drug administration, and syncope was not reported.
4) The blood pressure lowering effect may be enhanced by combined use with carperitide.
5) The QTc prolongation effect of amiodarone hydrochloride may be enhanced.
7. Administration to pregnant and lactating women
1) This drug cannot be used on women.
2) When 200 mg/kg/day was administered to pregnant rats during the organogenesis period, the implantation rate and male fetus weight decreased, and this dose represented a total systemic drug exposure to unbound sildenafil and its major metabolites that was more than 60 times the exposure observed when 100 mg, the maximum recommended dose for humans, was administered to males.
3) In perinatal and lactation tests using rats, the number of litters decreased when 60 mg/kg was administered, and the maximum dose at which no adverse reactions were observed in perinatal and lactation development tests on rats was 30 mg/kg/day administered for 36 days. In non-pregnant rats, the AUC at this dose was approximately 20 times the AUC observed in humans.
4) There is no experience in administering to pregnant or lactating women.
8. Administration to children
This drug cannot be used in newborns or children under the age of 18 (see ‘2. Do not administer to the following patients’).
9. Administration to elderly people
The clearance of sildenafil was reduced in older healthy volunteers (over 65 years of age). If the plasma concentration is high, both the effect and the rate of adverse reactions may increase, so 25 mg should be considered as the initial dose.
10. Treatment in case of overdose
1) In a study on healthy volunteers, when a single dose of up to 800 mg was administered, adverse reactions were similar to those of low doses, but the incidence and severity of adverse reactions increased. When 200 mg was administered, the effect did not increase, but the frequency of adverse reactions (headache, flushing, dizziness, indigestion, nasal congestion, visual abnormalities) and the severity of symptoms increased. The frequency of adverse reactions when administered at 100 mg was higher than that reported at the recommended dose range of 25 to 50 mg.
2) In case of overdose, usual symptomatic treatment should be administered. Sildenafil has a high plasma protein binding rate and is not excreted through urinary tract, so it cannot increase clearance through renal dialysis.
11. Storage and handling precautions
1) Keep out of reach of children.
2) Be careful because changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
12. Others
1) In terms of total systemic drug exposure (AUCs) for sildenafil and its main metabolites, sildenafil did not show carcinogenicity when administered to male and female rats for 24 months at doses equivalent to 29 and 42 times, respectively, the exposure observed when administered the highest recommended dose of 100 mg.
2) Sildenafil did not show carcinogenicity when administered to mice for 18-21 months up to the highest tolerated dose (MTD) of 10 mg per kg per day, which is approximately 0.6 times the highest recommended human dose based on body surface area (mg/m2). However, the total systemic exposure to sildenafil and its main metabolites was lower than the exposure observed when the highest recommended dose was administered to men.
3) In a 1-month oral toxicity test in rats, mesenteric arteritis was reported at doses of 45 mg/kg and 200 mg/kg. However, it was not observed in a 6-month toxicity test and carcinogenicity test in rats. In a 6- and 12-month long-term oral toxicity study in beagle dogs, idiopathic juvenile polyarteritis was reported in males at the highest dose of 50 mg/kg. It is thought that it is unlikely that these changes will also apply to humans.
4) Sildenafil was negative in an in vitro bacterial test to verify mutagenicity, an ovarian cell analysis test of Chinese hamsters, and an in vitro human lymphocyte test and in vivo mouse micronucleus test to verify chromosomal abnormality induction.
5) When doses up to 60 mg per kg per day, which is an AUC value more than 25 times the human AUC, were administered to females for 36 days and to males for 102 days, there was no decrease in reproductive function.
6) After oral administration of a single dose of 100 mg to healthy male volunteers, there was no effect on sperm motility or morphology.
7) There is no information on the effects of sildenafil on semen production and sperm motility/morphology in patients with erectile dysfunction.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
8 tablets (4 tablets/PTP
7. Expiration date
36 months from date of manufacture
1 tablet
- Active ingredient: Sildenafil citrate (USP)----70.23mg (50mg as sildenafil)
- Additives (tar color aluminum lake): Red No. 3, Red No. 40, Blue No. 2
- Other additives: Anhydrous calcium hydrogen phosphate, microcrystalline cellulose, magnesium stearate, Opadry II purple (85F600000), Opadry FX silver (62W28547), croscarmellose sodium
2. Effectiveness
Treatment of erectile dysfunction
3. Dosage and dosage
As sildenafil, the recommended dose of 25 to 50 mg is administered orally once a day about 1 hour before sexual activity, and in some cases, it can be administered 4 hours to 30 minutes before sexual activity.
The dosage may be increased or decreased depending on effectiveness and tolerability.
In the following patients, the initial dose should be adjusted to 25 mg because the plasma concentration of sildenafil may increase.
- Age 65 or older (AUC 40% increase)
- Liver failure (cirrhosis: 80%)
- Severe renal failure (creatinine clearance less than 30 mL/min: 100%)
- When used in combination with CYP3A4 inhibitors (ketoconazole, itraconazole, erythromycin (182%), etc., saquinavir (210%)), the effect and adverse reaction rate may increase as the blood concentration increases.
- For patients taking ritonavir concomitantly, the maximum single dose should not exceed 25 mg over 48 hours.
4. Precautions for use
1. Warning
1) If any type of nitrate preparation or NO donor (nitroglycerin, amine nitrite, isosorbide nitrate) is taken before, during or after treatment with this drug, the blood pressure lowering effect may be enhanced and blood pressure may fall excessively. Therefore, the doctor must sufficiently confirm that the patient has not taken nitrate preparations or NO donor before prescribing this drug, and avoid administering nitrate preparations or NO donor during and after treatment with this drug. Be careful.
2) In foreign countries, as a result of post-marketing adverse reaction monitoring, adverse reactions such as death due to cardiovascular adverse reactions have been reported, so the presence or absence of cardiovascular disorders must be sufficiently confirmed.
3) Since the possibility of cardiac risk increases when patients with cardiovascular disease engage in sexual activity, treatments for erectile dysfunction, including this drug, should not be used in patients for whom sexual activity is not recommended considering the cardiovascular condition.
4) This drug has systemic vasodilatory properties (mean maximum reduction: 8.4/5.5 mmHg), resulting in a transient decrease in supine blood pressure in healthy volunteers. This may not be important in normal patients, but before administering this drug, doctors and pharmacists should carefully consider the possibility that patients with underlying cardiovascular diseases may experience adverse reactions due to this vasodilation effect, especially when engaging in sexual activity.
5) There is no established clinical data on the effectiveness or safety of this drug for the following patients. Caution must be exercised when administering this drug.
- Patients who have had life-threatening arrhythmia within the past 6 months
- Patients with heart failure or coronary artery disease causing unstable angina
- Patients with low blood pressure (less than 90/50) or patients with high blood pressure (more than 170/100)
- Patients with retinitis pigmentosa
6) Prolonged erection for more than 4 hours and priapism (painful erection for more than 6 hours) have been rarely reported after marketing. If an erection persists for more than 4 hours, you should immediately seek medical help and diagnosis. If priapism is not treated right away, it can cause penile tissue damage and permanent loss of erectile function.
7) Patients who have left ventricular outflow obstruction (e.g. aortic stenosis and idiopathic hypertrophic subaortic stenosis) or whose ability to autoregulate blood pressure is severely impaired may be sensitive to the action of vasodilators, including PDE5 inhibitors.
8) Concomitant use of ritonavir, a protease inhibitor, increases the blood concentration of sildenafil by approximately 11 times, so caution should be exercised when administering this drug to patients taking ritonavir. There are limited data from patients exposed to high doses of sildenafil. When exposed to high concentrations of sildenafil, the frequency of visual abnormalities was higher. Decreased blood pressure, syncope, and priapism have been reported in some healthy volunteers exposed to high doses of sildenafil (200-800 mg). To reduce the possibility of adverse reactions in patients taking ritonavir, it is recommended to take a reduced dose of sildenafil.
2. Do not administer to the following patients
1) Patients with hypersensitivity to this drug or its components
2) Patients who regularly or intermittently take any type of organic nitrate preparation (nitroglycerin, isosorbide nitrate, amine nitrite, sodium nitroprusside)
: If you need to take nitrate preparations after taking this medicine, it is not known when it is safe to take them. Based on the pharmacokinetic profile of a single 100 mg oral dose administered to healthy normal volunteers, the plasma concentration of this drug at 24 hours is approximately 2 ng/mL (peak plasma concentration is approximately 440 ng/mL).
In the following patients: those aged 65 years or older, those with liver failure (e.g., cirrhosis), those with severe renal insufficiency (e.g., creatinine clearance less than 30 mL/min), and those taking a strong inhibitor of CYP3A4 (e.g., erythromycin), plasma concentrations of this drug at 24 hours after dosing have been observed to be 3-8 times higher than those observed in healthy volunteers. Although the plasma concentration of sildenafil 24 hours after administration is much lower than the peak plasma concentration, it is not known whether it is safe to use nitrate drugs together at this time.
3) Patients for whom sexual activity is not recommended, including cardiovascular disease: Patients with severe cardiovascular disease such as unstable angina or severe heart failure.
4) Patients with severe liver failure
5) Patients with hypotension (blood pressure less than 90/50 mmHg) or uncontrolled hypertension (resting systolic blood pressure exceeding 170 mmHg, resting diastolic blood pressure exceeding 100 mmHg)
6) Patients who have had a life-threatening cerebral infarction, cerebral hemorrhage, stroke, or myocardial infarction within the past 6 months
7) Patients with retinitis pigmentosa (a small number of patients with retinitis pigmentosa have a genetic disease of PDE of the retina)
8) Patients taking other erectile dysfunction drugs (the safety and effectiveness of co-administration of this drug with other erectile dysfunction drugs has not been studied)
9) Patients who have lost vision in one eye due to nonarteritic anterior ischemic optic neuropathy (NAION), regardless of previous PDE5 inhibitor use.
10) Children and women under 18 years of age
11) Patients taking amiodarone hydrochloride (oral medication)
12) Patients taking guanylate cyclase stimulants such as Riociguat (potentially may cause symptomatic hypotension such as lowering blood pressure)
3. Administer with caution to the following patients:
1) Patients with anatomical deformity of the penis (angulation, corpora cavernosa fibrous tissue hyperplasia or Peyronie's disease)
2) Patients with conditions that may predispose to priapism (sickle cell disease, multiple myelopathy, leukemia)
3) Patients with bleeding abnormalities or active peptic ulcers (It appears to enhance the platelet aggregation inhibition effect of sodium nitroprusside. Safety in patients with bleeding abnormalities or active peptic ulcers has not been established.)
4) Elderly (since it has been observed that blood concentration increases in elderly people, the initial dose should be started with a low dose (25 mg).)
5) Patients with severe renal failure (creatinine clearance rate less than 30 mL/min) (Since an increase in plasma concentration was observed, the initial dose should be started with a low dose (25 mg).)
6) Patients with liver failure (since an increase in plasma concentration was observed, the initial dose should be started with a low dose (25 mg).)
7) Patients taking CYP3A4 inhibitors (since an increase in plasma concentration was observed, the initial dose should be started with a low dose (25 mg).)
8) Patients taking carperitide
9) Patients with diabetic retinopathy (As the safety of this drug in patients with diabetic retinopathy has not been studied, it should be administered after carefully conducting a benefit-harm evaluation.)
10) For patients who require the maximum recommended dose of 100 mg, the rate of adverse reactions may increase.
11) When administering to patients with cardiovascular disease who have not had sexual intercourse for several years, or patients with a history of cerebral infarction, cerebral hemorrhage, or myocardial infarction, the presence or absence of cardiovascular disease must be sufficiently confirmed. Before starting treatment with this drug, their cardiovascular status should be carefully evaluated.
In patients with cardiovascular risk factors, sexual activity may pose a potential cardiac risk. Patients who have experienced related symptoms (e.g., angina, dizziness, nausea) when starting sexual activity should refrain from further activities and consult a doctor or pharmacist about the symptoms.
12) Patients with multiple systemic atrophy (idiopathic orthostatic hypotension (Shy-Drager syndrome, etc.)) (The vasodilator action of this drug may worsen the hypotensive condition caused by the patient's underlying disease.)
4. Adverse reactions
Adverse reactions were generally transient and mild to moderate in severity. In fixed-dose studies, the incidence of some adverse reactions increased with dose. The adverse reaction characteristics of the variable-dose study, which more closely reflected the recommended dosage, were also similar to those of the fixed-dose study.
A. 74 double-blind, placebo-controlled phase 2//3/4 clinical trials
The most commonly reported adverse reactions were headache and flushing.
Adverse reactions reported in clinical trials (74 double-blind, placebo-controlled phase 2//3/4 trials) and post-marketing surveillance are listed in descending order of severity for each organ system as shown in [Table 1] below.
[Table 1] Adverse reactions reported in clinical trials and post-marketing surveillance
(Please refer to the attached document for further details)
*Adverse reactions reported only in post-marketing surveillance
At doses above the recommended dosage range, adverse reactions appeared similar to those above, but were generally reported more frequently.
B. Clinical trials for approval of Viagra
1) In six variable-dose, placebo-controlled clinical trials, the following adverse reactions were reported when this drug was administered at the recommended dose.
[Table 2.] (Please refer to the attached document for further details)
2) Among the adverse reactions that occurred in more than 2%, those that occurred at the same rate in the placebo group were as follows: respiratory tract infection, back pain, influenza syndrome, and joint pain.
3) In a fixed dose study, indigestion (17%) and visual abnormalities (11%) occurred more frequently at a dose of 100 mg than at doses lower than that. The above adverse reactions occurred at doses higher than the recommended dose, but the frequency was higher.
4) The following adverse reactions occurred in less than 2% of patients in 6 variable-dose, controlled clinical trials, but the causal relationship with this drug is not clear. Reported adverse reactions were those possibly related to drug use, and minor adverse reactions that were not accurate enough to be considered related were excluded.
(1) Whole body: infection, facial swelling, photosensitivity reaction, shock, asthenia, pain, chills, accidental fall, abdominal pain, allergic reaction, chest pain, accidental trauma.
(2) Cardiovascular system: angina, atrioventricular block, migraine, syncope†, tachycardia†, palpitations†, hypotension†, postural hypotension, myocardial ischemia, cerebral thrombosis, cardiac arrest, heart failure, electrocardiogram abnormalities, cardiomyopathy, vasodilatation.
(3) Digestive system: Nausea†, vomiting†, glossitis, colitis, dysphagia, gastritis, gastroenteritis, esophagitis, stomatitis, dry mouth†, liver function abnormality, rectal bleeding, gingivitis.
(4) Blood and lymphatic system: anemia and leukopenia.
(5) Metabolic and nutritional systems: thirst, edema, gout, unstable diabetes, hyperglycemia, peripheral edema, hyperuricemia, hypoglycemia, hypernatremia.
(6) Skeletal muscular system: arthritis, arthrosis, muscle pain†, tendon rupture, tenosynovitis, bone pain, myasthenia gravis, synovitis.
(7) Nervous system: Ataxia, hypertonia, neuralgia, neuropathy, paresthesia, tremor, dizziness, depression, insomnia, drowsiness†, dream abnormalities, decreased reflex function, decreased perception.
(8) Respiratory system: Asthma, difficulty breathing, laryngitis, pharyngitis, sinusitis, bronchitis, increased sputum, increased cough, rhinitis†.
(9) Skin and appendages: urticaria, herpes simplex, itching, sweating, skin ulcers, contact dermatitis, exfoliative dermatitis.
(10) Special organs: sudden hearing loss or hearing loss, mydriasis, conjunctivitis, glare†, tinnitus, eye pain†, otalgia, eye hemorrhage, cataract, dry eye syndrome†.
(11) Urogenital system: cystitis, enuresis, frequent urination, breast enlargement, urinary incontinence, ejaculation disorder, genital edema and dysorgasmia, and prostate abnormalities.
† Adverse reactions listed in Table 1
In an analysis of double-blind, placebo-controlled clinical trials with more than 1,300 person-years of observation for the sildenafil group and more than 700 person-years for the placebo group, there was no difference in the incidence of myocardial infarction and mortality due to cardiovascular disease in the patient group administered sildenafil compared to the placebo group. The incidence of myocardial infarction was 1.1 per 100 person-years in both the sildenafil and placebo groups. The mortality rate from cardiovascular disease was 0.3 per 100 person-years in both groups.
5) As a result of domestic clinical trials, it has been reported that the incidence of adverse reactions such as flushing, headache, and visual abnormalities is higher than the results of foreign clinical trials.
c. Post-marketing surveillance
1) Serious cardiovascular adverse reactions such as myocardial infarction, sudden cardiac death, ventricular arrhythmia, cerebrovascular hemorrhage, transient angina attack, and hypertension have been temporarily reported after marketing in relation to the use of this drug. Most of these patients had cardiovascular risk factors, and many of these adverse reactions occurred during or immediately after sexual activity, and in some cases, it was reported that they occurred immediately after using this drug without sexual activity. In other cases, it occurred several hours to several days after using this drug or having sexual intercourse. It is not known whether these adverse reactions are directly related to this drug, related to sexual activity, related to underlying cardiovascular disease, a combination of these factors, or due to other factors.
2) Sudden hearing loss or hearing loss was rarely reported after marketing, and this appeared to have a tentative correlation with PDE5 inhibitors, including this drug. In some cases, it has been reported that disease status and other factors may be associated with hearing-related adverse reactions, but in most cases, medical follow-up information that could support this association was not confirmed. It is not known whether these adverse reactions are directly related to the administration of this drug, due to the patient's inherent hearing loss risk factors, a combination of these, or other factors.
3) Tachycardia†, hypotension†, and syncope† have been reported after marketing.
4) In rare cases, there have been reports of hypotension as an adverse reaction after co-administration of sildenafil with α-blockers.
5) Other adverse reactions reported after marketing in relation to this drug, which have a tentative causal relationship with this drug, but which were not confirmed in pre-marketing clinical trials, are as follows.
(1) Nervous system: anxiety
(2) Genitourinary system: prolonged erection†, hematuria
(3) Vascular abnormalities: nosebleed†
(4) Systemic: Hypersensitivity†
(5) Eyes: Double vision, temporary loss of vision/reduced vision, redness, eye burning, eye swelling/pressure, increase in intraocular pressure, retinal vascular disease and hemorrhage, vitreous detachment/contraction and myoretinal macular edema, non-arterial anterior ischemic optic neuropathy*
† Adverse reactions listed in Table 1
*Non-arteritic anterior ischemic optic neuropathy (NAION), which causes vision decline, including permanent vision loss, has been rarely reported in post-marketing surveillance and has been shown to be tentatively related to all PDE5 inhibitors, including this drug. Most, but not necessarily, patients had anatomical or vascular risk factors that may predispose to non-arterial anterior ischemic optic neuropathy: low cup/disc ratio, age over 50 years, diabetes, hypertension, coronary artery disease, hyperlipidemia, and smoking.
An observational study evaluating whether recent use of PDE5 inhibitor drugs was associated with the acute onset of non-arterial anterior ischemic optic neuropathy showed that the risk of non-arterial anterior ischemic optic neuropathy increased approximately two-fold within 5 times the half-life after administration of PDE5 inhibitors. According to published literature, the annual incidence of non-arterial anterior ischemic optic neuropathy is 2.5-11.8 cases per year per 100,000 men aged 50 years or older.
6) Domestic post-marketing survey results
(1) Results of a usage survey conducted on 8,751 patients with erectile dysfunction
① As a result of a post-marketing use results survey conducted on 8,751 people for re-examination in Korea, the case rate of adverse reactions regardless of causal relationship with the drug was found to be 6.62% (579 people, 701 cases/8,751 people), and among these, adverse reactions for which a causal relationship with this drug could not be ruled out were 6.21% (543/8,751 people).
Flushing was the most frequently reported event at 3.75% (328/8,751 patients), followed by headache at 1.83% (160/8,751), dyspepsia at 0.23% (20/8,751), dizziness and palpitations at 0.22% each (19/8,751 each), ocular hyperemia at 0.15% (13/8,751), and visual disturbances at 0.11% (10/8,751).
In addition, adverse reactions reported less than 0.1% are classified by organ system as follows.
- Central and peripheral nervous system: migraine, confusion
- Digestive system: diarrhea, nausea, hiccups, dry mouth, vomiting, abdominal pain, dysphagia, gastric ulcer, gastroesophageal reflux, gastrointestinal disorders, abdominal distension
- Eyes: Visual impairment, double vision, dry eyes
- Cardiovascular system: tachycardia, vasodilatation, hypotension
- Respiratory system: rhinitis, nasal congestion, difficulty breathing, upper respiratory tract infection
- Liver and biliary system: increased AST, increased ALT
- Mental nervous system: anxiety, insomnia, somnolence
- Reproductive system: priapism, genital pain
- Others: redness of lips, edema, general warmth, facial edema, chest pain, asthenia, paresthesia, fatigue, increase in non-protein content, sweating, erythema, itching, muscle pain
② Among these, new adverse reactions that did not appear in pre-marketing clinical trials and a causal relationship with the drug cannot be ruled out were reported in 3 cases of general fever, 2 cases each of hiccups and erythema, and 1 case each of redness of the lips, gastric ulcer, gastroesophageal reflux, gastrointestinal disorder, and increased non-protein content.
(2) Result of spontaneous adverse reaction reporting
① Among the adverse reactions voluntarily reported after marketing in Korea, adverse reactions that were not confirmed in pre-marketing clinical trials but were assessed as having a tentative causal relationship with this drug in existing post-marketing investigations included redness of the eyes, priapism, decreased vision, increased intraocular pressure, hematuria, retinal vascular disease and hemorrhage, anxiety, temporary loss of vision, retinal detachment, epistaxis, eye swelling, and prolonged erection.
② The following adverse reactions are added according to the analysis and evaluation of domestic adverse reaction reporting data.
- Whole body: facial flushing, infection/tuberculosis, extremity pain
- Liver and biliary system: Hepatitis/Virus
- Urogenital system: penile dysfunction, painful urination, polyuria
- Eyes: Glaucoma, galactorrhea
- Neoplasm: Gastric carcinoma
- Skin: Seborrheic
D. Clinical trials in Japan
At the time of approval, adverse reactions were observed in 40 (25.48%) of 157 subjects who took this drug (doses used in the study: 25 mg to 50 mg), and abnormalities in clinical laboratory tests were observed in 31 (19.75%).
Frequently reported adverse reactions include headache (20 people; 12.74%), flushing (16 people; 10.19%), and visual abnormalities (chromopia 1 person, photophobia 1 person, conjunctivitis 1 person: a total of 3 people 1.91%). A frequently observed abnormality in clinical laboratory tests was an increase in creatine kinase (CK), which was observed in 9 of 132 cases (6.82%) receiving sildenafil.
Patients who experience the following adverse reactions should, if necessary, reduce the drug administration dose or discontinue administration and take appropriate measures to treat the adverse reactions. (Please refer to the attached document for details.)
5. General precautions
1) Patients eligible for this drug should be limited to those who require clinical treatment based on an objective diagnosis by conducting a medical history and examination to diagnose erectile dysfunction and underlying diseases.
2) Because sexual activity carries heart risks, you should pay attention to your cardiovascular condition before starting treatment. Because this drug has a blood pressure lowering effect through vasodilation, it can enhance the blood pressure lowering effect of nitrates or NO donors.
3) Patients who have experienced a cerebral infarction, cerebral hemorrhage, or myocardial infarction within the past 6 months should not take the drug. When administering the drug to a patient with a previous history of a cerebral infarction, cerebral hemorrhage, or myocardial infarction, the presence or absence of cardiovascular disease must be sufficiently confirmed.
4) Since it has been reported in animal experiments that sildenafil shows high affinity for the melanin-rich retina, caution should be exercised, such as performing ophthalmologic examinations, during long-term administration of this drug.
5) Effects on the ability to drive and use machines: In clinical trials, some patients who took this drug, especially when administered 100 mg, reported visual abnormalities and dizziness due to administration of this drug, so caution should be taken when driving or operating machines. Before patients drive or operate machinery, they should know how they react to this medication and their doctor should advise them accordingly.
6) When this drug is administered simultaneously to patients receiving alpha-blockers, symptomatic hypotension may be induced in rare cases in some patients. Therefore, when taking more than 25 mg of this drug and an alpha-blocker together, this drug should not be administered within 4 hours after administering the alpha-blocker. To minimize the occurrence of such postural hypotension, before using this drug for the first time, it must be confirmed that the patient is hemodynamically stable on alpha-blockers, and consideration should be given to starting the initial dose at a low dose. Additionally, doctors should instruct patients on what to do if symptoms of postural hypotension appear.
7) In a drug interaction study, when amlodipine 5 mg, 10 mg and Amlodipine 100 mg were co-administered to patients with hypertension, it was observed that diastolic blood pressure and systolic blood pressure decreased by an average of 7 mmHg and 8 mmHg, respectively. Drug interactions between this drug and other antihypertensive medications have not been studied.
8) This drug had no effect on bleeding time when taken alone or with aspirin. In vitro studies using human platelets show that sildenafil enhances the anti-aggregation effect of sodium nitroprusside. The combination of this drug and heparin has an additive effect on bleeding time in anesthetized rabbits, but this interaction has not been studied in humans.
9) If sudden vision loss occurs in the patient's eyes (one or both eyes), the doctor should advise the patient to stop using PDE5 inhibitors, including this drug, and take medical attention. These symptoms may be a sign of nonarteritic anterior ischemic optic neuropathy (NAION), a condition that causes vision decline, including permanent vision loss, which has been rarely reported in post-marketing surveillance and has been shown to be tentatively related to the administration of all PDE5 inhibitors, including this drug. If sudden vision loss occurs, patients should be informed to stop taking this medicine and consult a doctor immediately.
People who have previously experienced non-arterial anterior ischemic optic neuropathy are at a higher risk of recurrence of non-arterial anterior ischemic optic neuropathy. Therefore, doctors should inform these patients of these risks and that the use of PDE5 inhibitors may affect the occurrence of adverse reactions. Caution should be exercised when using PDE5 inhibitors, including this drug, in these patients, and should be used only when the expected benefits outweigh the risks.
10) If sudden hearing loss or hearing loss (which may be accompanied by tinnitus and dizziness) occurs, the doctor should advise the patient to stop using PDE5 inhibitors, including this drug, and seek immediate medical attention.
11) This drug is not an aphrodisiac or stamina enhancer, so it cannot be used for purposes other than the treatment of erectile dysfunction patients.
12) When taken with food, the onset of effect may be delayed compared to when administered on an empty stomach.
13) Use of this medicine cannot prevent diseases transmitted through sexual intercourse.
14) No tests have been conducted on the safety and effectiveness of co-administration of this drug with other PDE5 inhibitors, pulmonary arterial hypertension (PAH) treatments containing sildenafil, or other erectile dysfunction treatments, and such co-administration is not recommended.
6. Interaction
1) Drugs that increase blood concentration of this drug
(1) In in vitro studies, the metabolism of sildenafil is mainly mediated by CYP3A4 (major pathway) and 2C9 (minor pathway). Therefore, these CYP450 inhibitors may increase blood concentrations of sildenafil.
(2) In an in vivo study, cimetidine (800 mg), a non-specific CYP450 inhibitor, increased the plasma concentration of sildenafil by 56% when co-administered with this drug (50 mg) to healthy volunteers.
(3) Administration of a single 100 mg dose of this medicine during steady-state treatment with the moderate CYP3A4 inhibitor erythromycin (500 mg twice daily for 5 days) increased systemic exposure to sildenafil (AUC) by 182%. In a study in healthy male volunteers, coadministration of a single 100 mg dose with the HIV protease inhibitor saquinavir, a CYP3A4 inhibitor, at steady state (1,200 mg three times daily) increased sildenafil Cmax and AUC by 140% and 210%, respectively. More potent CYP3A4 inhibitors, such as ketoconazole and itraconazole, may have a greater effect.
(4) Patient population data from clinical studies showed a decrease in sildenafil clearance when coadministered with CYP3A4 inhibitors such as ketoconazole, erythromycin, or cimetidine.
(5) Systemic exposure to sildenafil increases when administered concurrently with CYP3A4 inhibitors, so the dose of this drug may need to be reduced depending on tolerability.
(6) Ritonavir, an HIV protease inhibitor, is a very strong CYP450 inhibitor. In a study on healthy male volunteers, when administered in steady state (500 mg, twice daily) with this drug (100 mg, single dose), the Cmax and AUC of sildenafil increased by 300% (4-fold) and 1000% (11-fold), respectively. Compared to the plasma concentration of about 5 ng/mL when sildenafil was administered alone, the plasma concentration was maintained at about 200 ng/mL even after 24 hours. This is consistent with the fact that ritonavir has pronounced effects on a wide range of CYP450 substrates.
(7) Although the interaction between other protease inhibitors and this drug has not been studied, it is expected that the blood concentration of sildenafil will increase when administered together.
(8) When the recommended dose of sildenafil was administered to patients taking a strong CYP3A4 inhibitor, the maximum free plasma concentration of sildenafil did not exceed 200 nM in any patient and was always well tolerated.
(9) In a study in healthy male volunteers, when the endothelin antagonist bosentan (CYP3A4 [moderate], CYP2C9 inducer and possibly CYP2C19 inducer) was coadministered at steady state (125 mg twice daily) with steady-state sildenafil (80 mg three times daily), the AUC and Cmax of sildenafil were 62.6%, respectively. and decreased by 55.4%. Sildenafil increased the AUC and Cmax of bosentan by 49.8% and 42%, respectively.
(10) When coadministered with a strong CYP3A4 inducer such as rifampin, a significant decrease in sildenafil plasma concentration is expected.
(11) Single administration of antacids (magnesium hydroxide/aluminum hydroxide) did not affect the bioavailability of this drug.
(12) As a result of population pharmacodynamic data analysis, CYP2C9 inhibitors such as tolbutamide and warfarin, SSRI agents (selective serotonin reuptake inhibitors), CYP2D6 inhibitors such as tricyclic antidepressants, thiazides and diuretics of this class, ACE inhibitors, and calcium channel blockers had no effect on the pharmacokinetics of sildenafil. The AUC of the active metabolite, N-desmethyl sildenafil, was increased by 62% by loop diuretics and potassium-sparing diuretics and by 102% by non-specific beta blockers. This effect on metabolites does not appear to be of clinical significance.
(13) In healthy male volunteers, there is no evidence that azithromycin (500 mg per day for 3 days) affects the AUC, Cmax, Tmax, elimination rate constant, and half-life of sildenafil or its major circulating metabolites.
(14) There is no information on the interaction between sildenafil and cyclosporine.
2) The effect of this drug on other drugs
(1) In in vitro studies, sildenafil is a mild inhibitor of CYP-450 isoforms 1A2, 2C9, 2C19, 2D6, 2E1, and 3A4 (IC50: > 150 μM). Considering that the peak plasma concentration of sildenafil after administration of the recommended dose is approximately 1 μM, this drug is unlikely to change the clearance of this isoenzyme substrate.
(2) In an in vivo study, when 100 mg of this drug was administered in combination with 5 mg and 10 mg of amlodipine to patients with hypertension, supine blood pressure decreased by an average of 8 mmHg and 7 mmHg in systolic and diastolic periods, respectively.
(3) There is no information on the interaction of this drug with non-specific PDE inhibitors such as theophylline or dipyridamole.
(4) In in vivo studies, there were no significant drug interactions with tolbutamide (250 mg) or warfarin (40 mg), which are metabolized by CYP2C9.
(5) This drug (50 mg) did not increase the delay in bleeding time caused by aspirin (150 mg).
(6) Sildenafil slightly reduces diastolic blood pressure in the supine and reclined positions (3.5 and 6.1 mmHg, respectively) in healthy subjects with a blood alcohol level of 80 mg/dL.
(7) Sildenafil (100 mg) did not affect the steady-state pharmacokinetics of the HIV protease inhibitors saquinavir and ritonavir, which are substrates for CYP3A4, in a study on healthy male volunteers.
(8) Sildenafil increased the AUC and Cmax of bosentan (125 mg, twice daily) by 49.8% and 42% in steady state (80 mg administered three times a day) (see 1) Drugs that increase blood concentration of this drug).
3) When the alpha-blocker doxazosin (4 mg and 8 mg) and sildenafil (25 mg, 50 mg, or 100 mg) were administered simultaneously to patients with benign prostatic hyperplasia receiving doxazosin, blood pressure in the lying position decreased by an average of 7/7 mmHg, 9/5 mmHg, and 8/4 mmHg, respectively, and blood pressure in the standing position decreased by an average of 6/6, respectively. A further decrease of mmHg, 11/4 mmHg, and 4/5 mmHg was observed. When sildenafil in doses higher than 25 mg were simultaneously administered to patients receiving doxazosin, patients who experienced symptomatic postural hypotension, including drowsiness and dizziness, were rarely reported within 1 to 4 hours after drug administration, and syncope was not reported.
4) The blood pressure lowering effect may be enhanced by combined use with carperitide.
5) The QTc prolongation effect of amiodarone hydrochloride may be enhanced.
7. Administration to pregnant and lactating women
1) This drug cannot be used on women.
2) When 200 mg/kg/day was administered to pregnant rats during the organogenesis period, the implantation rate and male fetus weight decreased, and this dose represented a total systemic drug exposure to unbound sildenafil and its major metabolites that was more than 60 times the exposure observed when 100 mg, the maximum recommended dose for humans, was administered to males.
3) In perinatal and lactation tests using rats, the number of litters decreased when 60 mg/kg was administered, and the maximum dose at which no adverse reactions were observed in perinatal and lactation development tests on rats was 30 mg/kg/day administered for 36 days. In non-pregnant rats, the AUC at this dose was approximately 20 times the AUC observed in humans.
4) There is no experience in administering to pregnant or lactating women.
8. Administration to children
This drug cannot be used in newborns or children under the age of 18 (see ‘2. Do not administer to the following patients’).
9. Administration to elderly people
The clearance of sildenafil was reduced in older healthy volunteers (over 65 years of age). If the plasma concentration is high, both the effect and the rate of adverse reactions may increase, so 25 mg should be considered as the initial dose.
10. Treatment in case of overdose
1) In a study on healthy volunteers, when a single dose of up to 800 mg was administered, adverse reactions were similar to those of low doses, but the incidence and severity of adverse reactions increased. When 200 mg was administered, the effect did not increase, but the frequency of adverse reactions (headache, flushing, dizziness, indigestion, nasal congestion, visual abnormalities) and the severity of symptoms increased. The frequency of adverse reactions when administered at 100 mg was higher than that reported at the recommended dose range of 25 to 50 mg.
2) In case of overdose, usual symptomatic treatment should be administered. Sildenafil has a high plasma protein binding rate and is not excreted through urinary tract, so it cannot increase clearance through renal dialysis.
11. Storage and handling precautions
1) Keep out of reach of children.
2) Be careful because changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
12. Others
1) In terms of total systemic drug exposure (AUCs) for sildenafil and its main metabolites, sildenafil did not show carcinogenicity when administered to male and female rats for 24 months at doses equivalent to 29 and 42 times, respectively, the exposure observed when administered the highest recommended dose of 100 mg.
2) Sildenafil did not show carcinogenicity when administered to mice for 18-21 months up to the highest tolerated dose (MTD) of 10 mg per kg per day, which is approximately 0.6 times the highest recommended human dose based on body surface area (mg/m2). However, the total systemic exposure to sildenafil and its main metabolites was lower than the exposure observed when the highest recommended dose was administered to men.
3) In a 1-month oral toxicity test in rats, mesenteric arteritis was reported at doses of 45 mg/kg and 200 mg/kg. However, it was not observed in a 6-month toxicity test and carcinogenicity test in rats. In a 6- and 12-month long-term oral toxicity study in beagle dogs, idiopathic juvenile polyarteritis was reported in males at the highest dose of 50 mg/kg. It is thought that it is unlikely that these changes will also apply to humans.
4) Sildenafil was negative in an in vitro bacterial test to verify mutagenicity, an ovarian cell analysis test of Chinese hamsters, and an in vitro human lymphocyte test and in vivo mouse micronucleus test to verify chromosomal abnormality induction.
5) When doses up to 60 mg per kg per day, which is an AUC value more than 25 times the human AUC, were administered to females for 36 days and to males for 102 days, there was no decrease in reproductive function.
6) After oral administration of a single dose of 100 mg to healthy male volunteers, there was no effect on sperm motility or morphology.
7) There is no information on the effects of sildenafil on semen production and sperm motility/morphology in patients with erectile dysfunction.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
8 tablets (4 tablets/PTP
7. Expiration date
36 months from date of manufacture
Product Updates
Total 4items
| No. | Product Name | Details | Date of Change | Download |
|---|---|---|---|---|
| 4 | Forte V tablet 50mg | Forte V tablets 50 mg (precautions for use... | 2017.08.09 | HWP)1.~96. Sildenafil (citrate) single agent (oral) unified adjustment ( |
| 3 | Forte V tablet 50mg | Forte V tablets 50 mg (precautions for use... | 2014.09.05 | HWPSildenafil, sildenafil citrate single drug unification adjustment (draft).hw |
| 2 | Forte V tablet 50mg | Forte V tablet 50mg (efficacy, dosage, usage... | 2013.12.30 | HWP)2012 Pharmaceutical Literature Re-evaluation (Forte V Tablet 100_Forte V |
| 1 | Forte V tablet 50mg | Forte V tablet 50mg (Precautions for use) | 2013.09.13 | HWPChanges and corrections in precautions for use of sildenafil single agent (oral).h |